Literature DB >> 2737287

Two isozymes of PKC found in HL-60 cells show a difference in activation by the phorbol ester TPA.

I Beh1, R Schmidt, E Hecker.   

Abstract

Cytosol from untreated cells and a detergent extract of the particulate fraction from TPA-treated HL-60 cells were analyzed for protein kinase C activity by consecutive column chromatography on Mono Q and hydroxyapatite. From both preparations two separate peaks of enzyme activity were obtained. The first peak, eluting at lower salt concentrations, is activated at lower TPA concentrations (3 X 10(-9) M) than the other (10(-7) M), which was eluted at higher salt concentrations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737287     DOI: 10.1016/0014-5793(89)80637-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Different protein kinase C isoforms are present in the yeast and mycelium forms of Sporothrix schenckii.

Authors:  E E Aquino-Piñero; N Rodríguez del Valle
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

2.  5-hydroxytryptamine-stimulated accumulation of 1,2-diacylglycerol in the rabbit basilar artery: a role for protein kinase C in smooth muscle contraction.

Authors:  A H Clark; C J Garland
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  The effect of putative protein kinase C inhibitors, K252a and staurosporine, on the human neutrophil respiratory burst activated by both receptor stimulation and post-receptor mechanisms.

Authors:  B Twomey; R E Muid; M M Dale
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

4.  Superoxide production by human eosinophils can be inhibited in an agonist-selective manner.

Authors:  M K Bach; J R Brashler; E N Petzold; M E Sanders
Journal:  Agents Actions       Date:  1992-01

Review 5.  Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

Authors:  A Gescher
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.